Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04796584 · ClinicalTrials.gov registry record
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
A clinical trial, sponsored by Providence Health & Services.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04796584 is a clinical trial that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 20 participants.
The verdict
NCT04796584 was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medications. We hypothesize that the use of immunomodulators in MS patients may eliminate or reduce the level of protective immune response, and/or shorten the duration of the protective response.
Interventions
- OTHER Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2022-10-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04796584
The ClinicalTrials.gov registry entry for NCT04796584 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus is the first listed.
NCT04796584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04796584 about?
NCT04796584 is a clinical study titled "Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication". The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medi...
What is the current status of trial NCT04796584?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2022-07-11. Estimated completion is 2022-10-25.
What interventions are being tested in trial NCT04796584?
The interventions under investigation include: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus (OTHER).
Who is sponsoring clinical trial NCT04796584?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.